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HIV incidence and 95% intervals by risk 
score using the full risk score (A) and a 
modified risk score that excluded variable for 
any curable STI at baseline and HSV-2 
serostatus (B). 
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Globally, 16 million women live with HIV, accounting for 50% of the HIV-infected adult population, 
this proportion being even higher in sub-Saharan Africa. Therefore, there is an imperative need to 
address the problem of new infections in women, who, in many social contexts, are also more 
exposed to violence, discrimination and economical dependence. The first step is to identify women 
who are highly exposed to HIV, in order to focus the prevention effort on those who needs it the 
most.  
Even though risk assessment tools exist for heterosexual serodiscordant couples in Africa and men 
who have sex with men in the United States, an effective method to identify women at risk of HIV 
infection in Africa had not yet been validated. Last month, a group of investigators at Fred Hutch, 
University of Washington, and different research institutions in South Africa published a method to 
determine the risk of HIV acquisition for African women. "In many settings in sub-Saharan Africa with 
generalized epidemics, it has been challenging to identify women who are at high risk of acquiring 
HIV", said Dr. Jennifer Balkus, a staff scientist working in the Vaccine and Infectious Disease 
Division and first author of the paper published in the Journal of Acquired Immunodeficiency 
Syndromes. 
To identify the factors that can predict HIV risk more efficiently, the investigators utilized data from 
the VOICE study, a placebo controlled trial aimed at evaluating safety and efficacy of oral tenofovir 
disoproxil fumarate (TDF), oral TDF/emtricitabine, and vaginal tenofovir gel for prevention of HIV 
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acquisition. The study represents a source of data on exposure and HIV acquisition between study 
participants. To validate the risk score obtained through the VOICE study, data from two other trials 
testing effectiveness of a microbicide gel (HIV prevention trial network 035) and oral TDF/FTC (FEM-
PrEP) for HIV prevention were utilized.  
Numerous factors were included in the calculation of the final score, including age, alcohol use, 
living situation (married or living with primary partner, partner provides financial support), curable 
sexually transmitted infections (STI) at baseline and HSV-2 serostatus. Given the lack of availability 
of data on alcohol consumption or STIs in the two validation studies and the possible difficulty to 
obtain such information in certain contexts, partial scoring systems excluding either variable (alcohol 
consumption or STI) were tested as well. For full and partial risk scores, a sharp increase in HIV 
incidence was observed for risk scores equal or higher than 5 (See figure). The validation confirmed 
high sensitivity and specificity of both full and partial scores, opening the use of this new score 
system. "Our risk score could be used in the context of HIV prevention in several ways: (1) it could 
be used as a screening tool for biomedical HIV prevention trials to target enrollment of women who 
may be at higher risk of acquiring HIV; and (2) it could be used in public health settings as part of the 
implementation and scale-up of biomedical HIV prevention interventions for women such as oral 
PrEP and the dapivirine vaginal ring, in order to target women who would benefit most from these 
important HIV prevention tools", explained Dr. Balkus. This new tool sheds light on a unique and 
previously underrepresented population, and with proper implementation can highly impact HIV 
prevention in women. 
The study was supported by National Institutes of Health and the University of Washington Center 
for AIDS Research. 
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